TW201642864A - 利伯西利（ｒｉｂｏｃｉｃｌｉｂ）錠劑 - Google Patents

利伯西利（ｒｉｂｏｃｉｃｌｉｂ）錠劑 Download PDF

Info

Publication number
TW201642864A
TW201642864A TW105111921A TW105111921A TW201642864A TW 201642864 A TW201642864 A TW 201642864A TW 105111921 A TW105111921 A TW 105111921A TW 105111921 A TW105111921 A TW 105111921A TW 201642864 A TW201642864 A TW 201642864A
Authority
TW
Taiwan
Prior art keywords
lozenge
tablet
core
weight ratio
libercilin
Prior art date
Application number
TW105111921A
Other languages
English (en)
Chinese (zh)
Inventor
賓胡馬哈分 古魯拉傑
阿諾德 葛連德瑞
魯伊 柯斯塔
Original Assignee
諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201642864(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 諾華公司 filed Critical 諾華公司
Publication of TW201642864A publication Critical patent/TW201642864A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105111921A 2015-04-16 2016-04-15 利伯西利（ｒｉｂｏｃｉｃｌｉｂ）錠劑 TW201642864A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562148240P 2015-04-16 2015-04-16

Publications (1)

Publication Number Publication Date
TW201642864A true TW201642864A (zh) 2016-12-16

Family

ID=55806565

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105111921A TW201642864A (zh) 2015-04-16 2016-04-15 利伯西利（ｒｉｂｏｃｉｃｌｉｂ）錠劑

Country Status (31)

Country Link
US (6) US10799506B2 (https=)
EP (3) EP3283058B1 (https=)
JP (1) JP2018514523A (https=)
KR (2) KR102750931B1 (https=)
CN (2) CN107530292B (https=)
AR (1) AR104257A1 (https=)
AU (5) AU2016248017A1 (https=)
BR (1) BR112017021283A2 (https=)
CA (1) CA2982425C (https=)
CL (1) CL2017002593A1 (https=)
CO (1) CO2017010510A2 (https=)
DK (2) DK3283058T3 (https=)
EA (1) EA201792290A1 (https=)
EC (1) ECSP17075052A (https=)
ES (2) ES2938261T3 (https=)
FI (2) FI3283058T3 (https=)
HR (2) HRP20260123T1 (https=)
HU (1) HUE061213T2 (https=)
IL (1) IL254818A0 (https=)
LT (1) LT4197530T (https=)
MX (1) MX2017013350A (https=)
PE (1) PE20180035A1 (https=)
PH (1) PH12017501820A1 (https=)
PL (2) PL4197530T3 (https=)
PT (2) PT4197530T (https=)
RS (1) RS67697B1 (https=)
SG (1) SG11201708084PA (https=)
SI (2) SI3283058T1 (https=)
TN (1) TN2017000422A1 (https=)
TW (1) TW201642864A (https=)
WO (1) WO2016166703A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
HUE061213T2 (hu) 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CA3048036A1 (en) 2018-07-02 2020-01-02 Apotex Inc Crystalline form of ribociclib succinate
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
CR20220342A (es) 2019-12-16 2023-01-23 Lunella Biotech Inc Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6
MX2022007487A (es) 2019-12-16 2022-08-04 Lunella Biotech Inc Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6.
CA3187241A1 (en) * 2020-08-03 2022-02-10 Krishna Murthy Bhavanasi Pharmaceutical compositions comprising ribociclib
WO2022071787A1 (es) * 2020-09-29 2022-04-07 Laboratorios Silanes S.A. De C.V. Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares
WO2022162122A1 (en) 2021-01-29 2022-08-04 Biotx.Ai Gmbh Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection
CN117396208A (zh) 2021-07-16 2024-01-12 达纳－法伯癌症研究所公司 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
TWI908143B (zh) 2022-01-25 2025-12-11 瑞士商諾華公司 瑞博西尼藥物組成物用於治療癌症之用途
WO2024049926A1 (en) 2022-08-31 2024-03-07 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof
KR20250163966A (ko) 2023-03-27 2025-11-21 노파르티스 아게 리보시클립과 아로마타제 저해제를 병용하여 초기 유방암을 치료하는 방법
TW202602868A (zh) 2024-04-15 2026-01-16 瑞士商諾華公司 瑞波西利的藥物組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5428812A (en) * 1977-08-09 1979-03-03 Yoshitomi Pharmaceut Ind Ltd Preparation of coated tablet
HU225964B1 (en) * 1994-07-12 2008-01-28 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
GB9414045D0 (en) 1994-07-12 1994-08-31 Berwind Pharma Service Moisture barrier film coating composition, method, and coated form
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
US8871263B2 (en) * 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
PT2872482T (pt) * 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
EP2742940B1 (en) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
US9867825B2 (en) * 2012-12-20 2018-01-16 Novartis Ag Pharmaceutical combination comprising binimetinib
UA118846C2 (uk) * 2013-03-21 2019-03-25 Новартіс Аг Комбінована терапія
EP2810644A1 (en) * 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
HUE061213T2 (hu) 2015-04-16 2023-05-28 Novartis Ag Ribociklib tabletta
CN109953966A (zh) * 2017-12-26 2019-07-02 天津耀辰实业发展有限公司 一种含有瑞博西尼的药物组合物及其制备方法
JP7347388B2 (ja) 2020-09-25 2023-09-20 信越化学工業株式会社 紫外線硬化型有機変性シリコーン組成物および硬化物

Also Published As

Publication number Publication date
AR104257A1 (es) 2017-07-05
AU2020250190A1 (en) 2020-11-05
ES3062263T3 (en) 2026-04-09
CN115554257A (zh) 2023-01-03
US20250134893A1 (en) 2025-05-01
US20250127785A1 (en) 2025-04-24
KR20170137101A (ko) 2017-12-12
AU2019201929B2 (en) 2020-07-09
EP3283058A1 (en) 2018-02-21
FI4197530T3 (fi) 2026-02-03
EA201792290A1 (ru) 2018-02-28
AU2022215155A1 (en) 2022-09-01
EP4197530B1 (en) 2025-11-12
US12064434B2 (en) 2024-08-20
EP4620458A2 (en) 2025-09-24
IL254818A0 (en) 2017-12-31
CA2982425C (en) 2023-10-31
SI3283058T1 (sl) 2023-03-31
PL3283058T3 (pl) 2023-03-20
MX2017013350A (es) 2018-01-25
PT3283058T (pt) 2023-02-03
HRP20230053T1 (hr) 2023-03-03
SI4197530T1 (sl) 2026-03-31
BR112017021283A2 (pt) 2018-06-26
WO2016166703A1 (en) 2016-10-20
PL4197530T3 (pl) 2026-03-23
CN107530292B (zh) 2022-11-01
EP4197530A1 (en) 2023-06-21
DK4197530T3 (da) 2026-02-09
HUE061213T2 (hu) 2023-05-28
US20230104792A1 (en) 2023-04-06
PH12017501820A1 (en) 2018-04-23
KR102750931B1 (ko) 2025-01-09
LT4197530T (lt) 2026-02-25
US10799506B2 (en) 2020-10-13
FI3283058T3 (fi) 2023-03-01
RS67697B1 (sr) 2026-02-27
ES2938261T3 (es) 2023-04-05
CN107530292A (zh) 2018-01-02
PE20180035A1 (es) 2018-01-09
SG11201708084PA (en) 2017-10-30
CA2982425A1 (en) 2016-10-20
DK3283058T3 (da) 2023-02-13
US12419894B2 (en) 2025-09-23
US20180071292A1 (en) 2018-03-15
CL2017002593A1 (es) 2018-05-18
EP4620458A3 (en) 2025-10-22
EP3283058B1 (en) 2022-11-16
AU2016248017A1 (en) 2017-10-19
PT4197530T (pt) 2026-02-05
AU2024227794A1 (en) 2024-11-21
AU2022215155B2 (en) 2024-08-01
TN2017000422A1 (en) 2019-01-16
AU2019201929A1 (en) 2019-04-11
HRP20260123T1 (hr) 2026-03-13
KR20250009572A (ko) 2025-01-17
US20200390771A1 (en) 2020-12-17
ECSP17075052A (es) 2018-02-28
JP2018514523A (ja) 2018-06-07
US20250090531A1 (en) 2025-03-20
CO2017010510A2 (es) 2018-03-20

Similar Documents

Publication Publication Date Title
TW201642864A (zh) 利伯西利（ｒｉｂｏｃｉｃｌｉｂ）錠劑
JP6402191B2 (ja) コリンアルホスセラートを含有するフィルムコーティング錠剤およびその製造方法
CA2847860A1 (en) Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
JP2024009815A (ja) アキシチニブを含有する医薬組成物
TW202408531A (zh) 包含葡萄糖酸內酯之哌柏西利製劑
HK40089304A (en) Ribociclib tablet
TWI726978B (zh) 一種含有喹啉衍生物或其鹽的藥物組成物
JP2020090484A (ja) エルロチニブを有効成分とする医薬錠剤
EA042324B1 (ru) Таблетка, содержащая рибоциклиб
HK1243319B (en) Ribociclib tablet
HK1243319A1 (en) Ribociclib tablet
JP2011126857A (ja) パロキセチン塩酸塩含有経口用錠剤
JP2017210493A (ja) ホリナートカルシウム含有錠
JP6673798B2 (ja) カペシタビンを有効成分とするフィルムコート医薬製剤
JP2019085425A (ja) ホリナートカルシウム含有錠